The global pharmaceutical industry is entering a structural acceleration phase of M&A, rather than a simple cyclical upswing. The core driver has shifted from periods of abundant capital and occasional mega-deals to persistent growth anxiety.
As the patent cliff approaches in a concentrated wave, while the development cycle for innovative drugs has not significantly shortened,...
Portuguese 
English
Arabic
French
Spanish
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek